Enhanced phagocytic activity of HIV-specific antibodies correlates with natural production of immunoglobulins with skewed affinity for FcγR2a and FcγR2b

Journal of Virology

Volumn 87, Issue 10, 2013, Pages 5468-5476

  Ackerman, Margaret E ^a,b   Dugast, Anne Sophie ^b   McAndrew, Elizabeth G ^b   Tsoukas, Stephen ^b   Licht, Anna F ^b   Irvine, Darrell J ^b,c   Alter, Galit ^b  

^a DARTMOUTH COLLEGE   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c Massachusetts Institute of Technology Cambridge   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FC RECEPTOR IIA; FC RECEPTOR IIB; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; IMMUNOGLOBULIN G;

ADAPTIVE IMMUNITY; ANTIGEN ANTIBODY COMPLEX; ANTIGEN BINDING; ARTICLE; CHEMOKINESIS; CONTROLLED STUDY; CYTOKINE RELEASE; EFFECTOR CELL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOGLOBULIN PRODUCTION; IMMUNOMODULATION; IMMUNOREGULATION; MAJOR CLINICAL STUDY; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; PROTEIN PROTEIN INTERACTION; VIRAL CLEARANCE; VIRUS ENTRY; VIRUS INHIBITION;

ANTIBODY AFFINITY; ANTIGEN-ANTIBODY COMPLEX; HIV; HIV ANTIBODIES; HIV INFECTIONS; HUMANS; PHAGOCYTOSIS; RECEPTORS, IGG;

EID: 84877316930     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.03403-12     Document Type: Article

References (60)

1. Takai T. 2005. Fc receptors and their role in immune regulation and autoimmunity. J. Clin. Immunol. 25:1-18.
2. Aasa-Chapman MM, Holuigue S, Aubin K, Wong M, Jones NA, Cornforth D, Pellegrino P, Newton P, Williams I, Borrow P, McKnight A. 2005. Detection of antibody-dependent complement-mediated inactivation of both autologous and heterologous virus in primary human immunodeficiency virus type 1 infection. J. Virol. 79:2823-2830.
3. Ackerman ME, Dugast AS, Alter G. 2012. Emerging concepts on the role of innate immunity in the prevention and control of HIV infection. Annu. Rev. Med. 63:113-130.
4. Ackerman ME, Moldt B, Wyatt RT, Dugast AS, McAndrew E, Tsoukas S, Jost S, Berger CT, Sciaranghella G, Liu Q, Irvine DJ, Burton DR, Alter G. 2011. A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples. J. Immunol. Methods 366:8 -19.
5. Ahmad R, Sindhu ST, Toma E, Morisset R, Vincelette J, Menezes J, Ahmad A. 2001. Evidence for a correlation between antibody-dependent cellular cytotoxicity-mediating anti-HIV-1 antibodies and prognostic predictors of HIV infection. J. Clin. Immunol. 21:227-233.
6. Burton DR, Dwek RA. 2006. Immunology. Sugar determines antibody activity. Science 313:627- 628.
7. Spiegelberg HL. 1974. Biological activities of immunoglobulins of different classes and subclasses. Adv. Immunol. 19:259 -294.
8. Forthal DN, Landucci G, Haubrich R, Keenan B, Kuppermann BD, Tilles JG, Kaplan J. 1999. Antibody-dependent cellular cytotoxicity independently predicts survival in severely immunocompromised human immunodeficiency virus-infected patients. J. Infect. Dis. 180:1338 -1341.
9. Hessell AJ, Hangartner L, Hunter M, Havenith CE, Beurskens FJ, Bakker JM, Lanigan CM, Landucci G, Forthal DN, Parren PW, Marx PA, Burton DR. 2007. Fc receptor but not complement binding is important in antibody protection against HIV. Nature 449:101-104.
10. Sawyer LA, Katzenstein DA, Hendry RM, Boone EJ, Vujcic LK, Williams CC, Zeger SL, Saah AJ, Rinaldo CR, Jr, Phair JP, et al. 1990. Possible beneficial effects of neutralizing antibodies and antibodydependent, cell-mediated cytotoxicity in human immunodeficiency virus infection. AIDS Res. Hum. Retroviruses 6:341-356.
11. Tomaras GD, Yates NL, Liu P, Qin L, Fouda GG, Chavez LL, Decamp AC, Parks RJ, Ashley VC, Lucas JT, Cohen M, Eron J, Hicks CB, Liao HX, Self SG, Landucci G, Forthal DN, Weinhold KJ, Keele BF, Hahn BH, Greenberg ML, Morris L, Karim SS, Blattner WA, Montefiori DC, Shaw GM, Perelson AS, Haynes BF. 2008. Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulinM( IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J. Virol. 82:12449- 12463.
12. Tyler DS, Lyerly HK, Weinhold KJ. 1989. Anti-HIV-1 ADCC. AIDS Res. Hum. Retroviruses 5:557-563.
13. Bouglé A, Max A, Mongardon N, Grimaldi D, Pene F, Rousseau C, Chiche JD, Bedos JP, Vicaut E, Mira JP. 2012. Protective effects of FCGR2A polymorphism in invasive pneumococcal diseases. Chest 142: 1474-1481.
14. Cheung NK, Sowers R, Vickers AJ, Cheung IY, Kushner BH, Gorlick R. 2006. FCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colony-stimulating factor. J. Clin. Oncol. 24:2885-2890.
15. Smith KG, Clatworthy MR. 2010. FcgammaRIIB in autoimmunity and infection: evolutionary and therapeutic implications. Nat. Rev. Immunol. 10:328 -343.
16. van der Pol WL, van den Berg LH, Scheepers RH, van der Bom JG, van Doorn PA, van Koningsveld R, van den Broek MC, Wokke JH, van de Winkel JG. 2000. IgG receptor IIa alleles determine susceptibility and severity of Guillain-Barre syndrome. Neurology 54:1661-1665.
17. van Sorge NM, van der Pol WL, van de Winkel JG. 2003. FcgammaR polymorphisms: implications for function, disease susceptibility and immunotherapy. Tissue Antigens 61:189 -202.
18. Bruhns P. 2012. Properties of mouse and human IgG receptors and their contribution to disease models. Blood 119:5640 -5649.
19. Clynes R, Maizes JS, Guinamard R, Ono M, Takai T, Ravetch JV. 1999. Modulation of immune complex-induced inflammation in vivo by the coordinate expression of activation and inhibitory Fc receptors. J. Exp. Med. 189:179 -185.
20. Samuelsson A, Towers TL, Ravetch JV. 2001. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 291:484- 486.
21. Forthal DN, Landucci G, Bream J, Jacobson LP, Phan TB, Montoya B. 2007. FcgammaRIIa genotype predicts progression of HIV infection. J. Immunol. 179:7916 -7923.
22. Brouwer KC, Lal RB, Mirel LB, Yang C, van Eijk AM, Ayisi J, Otieno J, Nahlen BL, Steketee R, Lal AA, Shi YP. 2004. Polymorphism of Fc receptor IIa for IgG in infants is associated with susceptibility to perinatal HIV-1 infection. AIDS 18:1187-1194.
23. Ngo-Giang-Huong N, Candotti D, Goubar A, Autran B, Maynart M, Sicard D, Clauvel JP, Agut H, Costagliola D, Rouzioux C. 2001. HIV type 1-specific IgG2 antibodies: markers of helper T cell type 1 response and prognostic marker of long-term nonprogression. AIDS Res. Hum. Retroviruses 17:1435-1446.
24. Dugast AS, Tonelli A, Berger CT, Ackerman ME, Sciaranghella G, Liu Q, Sips M, Toth I, Piechocka-Trocha A, Ghebremichael M, Alter G. 2011. Decreased Fc receptor expression on innate immune cells is associated with impaired antibody-mediated cellular phagocytic activity in chronically HIV-1 infected individuals. Virology 415:160 -167.
25. Huber M, Fischer M, Misselwitz B, Manrique A, Kuster H, Niederost B, Weber R, von Wyl V, Gunthard HF, Trkola A. 2006. Complement lysis activity in autologous plasma is associated with lower viral loads during the acute phase of HIV-1 infection. PLoS Med. 3:e441. doi:10.1371 /journal.pmed.0030441.
26. Lambotte O, Ferrari G, Moog C, Yates NL, Liao HX, Parks RJ, Hicks CB, Owzar K, Tomaras GD, Montefiori DC, Haynes BF, Delfraissy JF. 2009. Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. AIDS 23:897-906.
27. Moldt B, Shibata-Koyama M, Rakasz EG, Schultz N, Kanda Y, Dunlop DC, Finstad SL, Jin C, Landucci G, Alpert MD, Dugast AS, Parren PW, Nimmerjahn F, Evans DT, Alter G, Forthal DN, Schmitz JE, Iida S, Poignard P, Watkins DI, Hessell AJ, Burton DR. 2012. A nonfucosylated variant of the anti-HIV-1 MAb b12 has enhanced FcγRIIIa-mediated antiviral activity in vitro but does not improve protection against mucosal SHIV challenge in macaques. J. Virol. 86:6189-6196.
28. Holl V, Hemmerter S, Burrer R, Schmidt S, Bohbot A, Aubertin AM, Moog C. 2004. Involvement of Fc gamma RI (CD64) in the mechanism of HIV-1 inhibition by polyclonal IgG purified from infected patients in cultured monocyte-derived macrophages. J. Immunol. 173:6274-6283.
29. Holl V, Peressin M, Schmidt S, Decoville T, Zolla-Pazner S, Aubertin AM, Moog C. 2006. Efficient inhibition of HIV-1 replication in human immature monocyte-derived dendritic cells by purified anti-HIV-1 IgG without induction of maturation. Blood 107:4466-4474.
30. Tudor D, Bomsel M. 2011. The broadly neutralizing HIV-1 IgG 2F5 elicits gp41-specific antibody-dependent cell cytotoxicity in a FcgammaRI- dependent manner. AIDS 25:751-759.
31. Florese RH, Van Rompay KK, Aldrich K, Forthal DN, Landucci G, Mahalanabis M, Haigwood N, Venzon D, Kalyanaraman VS, Marthas ML, Robert-Guroff M. 2006. Evaluation of passively transferred, nonneutralizing antibody-dependent cellular cytotoxicity-mediating IgG in protection of neonatal rhesus macaques against oral SIVmac251 challenge. J. Immunol. 177:4028-4036.
32. Alter G, Martin MP, Teigen N, Carr WH, Suscovich TJ, Schneidewind A, Streeck H, Waring M, Meier A, Brander C, Lifson JD, Allen TM, Carrington M, Altfeld M. 2007. Differential natural killer cell-mediated inhibition of HIV-1 replication based on distinct KIR/HLA subtypes. J. Exp. Med. 204:3027-3036.
33. Moldt B, Schultz N, Dunlop DC, Alpert MD, Harvey JD, Evans DT, Poignard P, Hessell AJ, Burton DR. 2011. A panel of IgG1 b12 variants with selectively diminished or enhanced affinity for Fcgamma receptors to define the role of effector functions in protection against HIV. J. Virol. 85:10572-10581.
34. Terai I, Kobayashi K, Vaerman JP, Mafune N. 2006. Degalactosylated and/or denatured IgA, but not native IgA in any form, bind to mannosebinding lectin. J. Immunol. 177:1737-1745.
35. Veri MC, Gorlatov S, Li H, Burke S, Johnson S, Stavenhagen J, Stein KE, Bonvini E, Koenig S. 2007. Monoclonal antibodies capable of discriminating the human inhibitory Fcgamma-receptor IIB (CD32B) from the activating Fcgamma-receptor IIA (CD32A): biochemical, biological and functional characterization. Immunology 121:392- 404.
36. McAndrew EG, Dugast AS, Licht AF, Eusebio JR, Alter G, Ackerman ME. 2011. Determining the phagocytic activity of clinical antibody samples. J. Vis. Exp. 2011:e3588. doi:10.3791/3588.
37. Cox D, Greenberg S. 2001. Phagocytic signaling strategies: Fc(gamma)receptor- mediated phagocytosis as a model system. Semin. Immunol. 13:339- 345.
38. Grage-Griebenow E, Flad HD, Ernst M, Bzowska M, Skrzeczynska J, Pryjma J. 2000. HumanMOsubsets as defined by expression of CD64 and CD16 differ in phagocytic activity and generation of oxygen intermediates. Immunobiology 202:42-50.
39. Kekow J, Hobusch G, Gross WL. 1988. Predominance of the IgG1 subclass in the hypergammaglobulinemia observed in pre-AIDS and AIDS. Cancer Detect. Prev. 12:211-216.
40. Moore JS, Wu X, Kulhavy R, Tomana M, Novak J, Moldoveanu Z, Brown R, Goepfert PA, Mestecky J. 2005. Increased levels of galactosedeficient IgG in sera of HIV-1-infected individuals. AIDS 19:381-389.
41. Ackerman M, et al. In press.
42. Nimmerjahn F, Ravetch JV. 2005. Divergent immunoglobulin G subclass activity through selective Fc receptor binding. Science 310:1510 -1512.
43. Poonia B, Kijak GH, Pauza CD. 2010. High affinity allele for the gene of FCGR3A is risk factor for HIV infection and progression. PLoS One 5:e15562. doi:10.1371/journal.pone.0015562.
44. Florese RH, Demberg T, Xiao P, Kuller L, Larsen K, Summers LE, Venzon D, Cafaro A, Ensoli B, Robert-Guroff M. 2009. Contribution of nonneutralizing vaccine-elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccines. J. Immunol. 182:3718 -3727.
45. Van Rompay KK, Berardi CJ, Dillard-Telm S, Tarara RP, Canfield DR, Valverde CR, Montefiori DC, Cole KS, Montelaro RC, Miller CJ, Marthas ML. 1998. Passive immunization of newborn rhesus macaques prevents oral simian immunodeficiency virus infection. J. Infect. Dis. 177: 1247-1259.
46. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E, Benenson M, Gurunathan S, Tartaglia J, McNeil JG, Francis DP, Stablein D, Birx DL, Chunsuttiwat S, Khamboonruang C, Thongcharoen P, Robb ML, Michael NL, Kunasol P, Kim JH. 2009. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361: 2209-2220.
47. Richards JO, Karki S, Lazar GA, Chen H, Dang W, Desjarlais JR. 2008. Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cells. Mol. Cancer Ther. 7:2517-2527.
48. Hunt PW, Brenchley J, Sinclair E, McCune JM, Roland M, Page-Shafer K, Hsue P, Emu B, Krone M, Lampiris H, Douek D, Martin JN, Deeks SG. 2008. Relationship between T cell activation and CD4+T cell count in HIV-seropositive individuals with undetectable plasma HIVRNAlevels in the absence of therapy. J. Infect. Dis. 197:126 -133.
49. Brown EP, Licht AF, Dugast AS, Choi I, Bailey-Kellogg C, Alter G, Ackerman ME. 2012. High-throughput, multiplexed IgG subclassing of antigen-specific antibodies from clinical samples. J. Immunol. Methods 386:117-123.
50. Peipp M, Lammerts van Bueren JJ, Schneider-Merck T, Bleeker WW, Dechant M, Beyer T, Repp R, van Berkel PH, Vink T, van de Winkel JG, Parren PW, Valerius T. 2008. Antibody fucosylation differentially impacts cytotoxicity mediated by NK and PMN effector cells. Blood 112: 2390-2399.
51. Anderson P, Caligiuri M, O'Brien C, Manley T, Ritz J, Schlossman SF. 1990. Fc gamma receptor type III (CD16) is included in the zeta NK receptor complex expressed by human natural killer cells. Proc. Natl. Acad. Sci. U. S. A. 87:2274 -2278.
52. Shields RL, Lai J, Keck R, O'Connell LY, Hong K, Meng YG, Weikert SH, Presta LG. 2002. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibodydependent cellular toxicity. J. Biol. Chem. 277:26733-26740.
53. Shashidharamurthy R, Zhang F, Amano A, Kamat A, Panchanathan R, Ezekwudo D, Zhu C, Selvaraj P. 2009. Dynamics of the interaction of human IgG subtype immune complexes with cells expressing R and H allelic forms of a low-affinity Fc gamma receptor CD32A. J. Immunol. 183:8216-8224.
54. French MA, Tanaskovic S, Law MG, Lim A, Fernandez S, Ward LD, Kelleher AD, Emery S. 2010. Vaccine-induced IgG2 anti-HIV p24 is associated with control of HIV in patients with a 'high-affinity' Fcgamma- RIIa genotype. AIDS 24:1983-1990.
55. Sips M, Sciaranghella G, Diefenbach T, Dugast AS, Berger CT, Liu Q, Kwon D, Ghebremichael M, Estes JD, Carrington M, Martin JN, Deeks SG, Hunt PW, Alter G. 2012. Altered distribution of mucosal NK cells during HIV infection. Mucosal Immunol. 5:30-40.
56. Igietseme JU, Eko FO, He Q, Black CM. 2004. Antibody regulation of T-cell immunity: implications for vaccine strategies against intracellular pathogens. Expert Rev. Vaccines 3:23-34.
57. Ng CT, Jaworski JP, Jayaraman P, Sutton WF, Delio P, Kuller L, Anderson D, Landucci G, Richardson BA, Burton DR, Forthal DN, Haigwood NL. 2010. Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques. Nat. Med. 16:1117-1119.
58. Geier H, Celli J. 2011. Phagocytic receptors dictate phagosomal escape and intracellular proliferation of Francisella tularensis. Infect. Immun. 79:2204 -2214.
59. Joller N, Weber SS, Muller AJ, Sporri R, Selchow P, Sander P, Hilbi H, Oxenius A. 2010. Antibodies protect against intracellular bacteria by Fc receptor-mediated lysosomal targeting. Proc. Natl. Acad. Sci. U. S. A. 107: 20441-20446.
60. Liu Y, Gao X, Masuda E, Redecha PB, Blank MC, Pricop L. 2006. Regulated expression of FcgammaR in human dendritic cells controls cross-presentation of antigen-antibody complexes. J. Immunol. 177: 8440-8447.